#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně


Authors: Bayer Milan;  Horák Pavel;  Palička Vladimír;  Pavelka Karel;  Pikner Richard;  Rosa Jan;  Šenk František;  Vyskočil Václav;  Zikán Vít
Published in: Clinical Osteology 2018; 23(1): 32-37
Category:

Overview

One characteristic of bisphosphonates, the most widely used group of antiresorptive drugs for osteoporosis, is their long retention in the skeletal system and persistence of the effect following treatment discontinuation. Compared to bisphosphonates, intervention of denosumab into the bone metabolism is deeper, however it is not deposited in the bone tissue and after its use is discontinued, increase in bone remodelling exceeds the initial level (rebound effect) within 12-18 months from the last dose, which is associated with accelerated decrease in bone mineral density (BMD). A series of case reports and analysis of patients who discontinued the use of denosumab within the study FREEDOM and its extension, have shown that this phenomenon may in some cases lead to an increased risk of multiple vertebral fractures (Rebound-Associated Vertebral Fractures, RAVF), in particular in patients with prevalent vertebral body fractures. Denosumab therapy should be long-term. The outcomes of analyses of smaller-scale clinical studies show that, in case it has been stopped, it must be followed by another antiresorptive treatment (typically with bisphosphonates). The opinion of the SMOS Working Group discusses the currently available data on the efficiency of different options of using bisphosphonates after stopping denosumab therapy, and proposes a care pattern for patients who ended this antiresorptive treatment for osteoporosis.

Key words:

denosumab – bisphosphonates – bone remodelling markers – brebound response – bone mineral density – vertebral fractures

Received 5. 9. 2018


Sources
  1. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Longterm Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927–2938.

  2. Black DM, Reid IR, Cauley JA et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015; 30(5): 934–944.

  3. Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29(1): 1–23.

  4. Khan AA, Morrison A, Hanley DA et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30(1): 3–23.

  5. Bone HG, Wagman RB, Brandi ML et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017; 5(7): 513-523.

  6. Compston J. Safety of long-term osteoporosis therapy for osteoporosis. Lancet Diabetes Endocrinol 2017; 5(7): 485-487.

  7. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on Bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96(4): 972-980.

  8. Miller PD, Bolognese MA, Lewieckie EM et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008; 43(2): 222-229.

  9. McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteopor Int 2017; 28(5): 1723-1732.

  10. McClung MR. Cancel the denosumab holiday. Osteoporos Int 2016; 27(5): 1677–1682.

  11. Anastasilakis AD, Yavropoulou MP, Makras P et al. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 2017; 176(6): 677–683.

  12. Brown JP, Roux C, Törring O et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res 2013; 28(4): 746–752.

  13. Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 2016; 27(5): 1929–1930.

  14. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D et al. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 2016; 27(5): 1923–1925.

  15. Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab - from clinic and biomechanics. Osteoporos Int 2016; 27(5): 1917–1921.

  16. Lamy O, Gonzalez-Rodriguez E, Stoll D et al. Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical case report. J Clin Endocrinol Metab 2017; 102(2): 354–358.

  17. Polyzos SA, Terpos E. Clinical vertebral fractures following denosumab discontinuation. Endocrine 2016; 54(1): 271–272.

  18. Anastasilakis AD, Polyzos SA, Makras P et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017; 32(6): 1291–1296.

  19. Tripto-Shkolnik L, Rouach V, Marcus Y et al. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates. Calcif Tissue Int 2018; 103(1): 44-49.

  20. Cummings SR, Ferrari S, Eastell R et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 2018; 33(2): 190-198.

  21. Tsourdi E, Langdahl B, Cohen-Solal M et al. Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone 2017; 105(1): 11–17.

  22. Trovas G. Letter to the editor: severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab 2017; 102(3): 1083.

  23. Uebelhart B, Rizzoli R, Ferrari SL. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int 2017; 28(9): 2701–2705.

  24. Freemantle N, Satram-Hoang S, Tang ET et al. (DAPS Investigators). Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012; 23(1): 317-326.

  25. Reid IR, Horne AM, Mihov B et al. Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 2017; 101(4): 371-374.

  26. Leder BZ, Tsai JN, Jiang LA et al. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-Follow-Up). Bone 2017; 98: 54–58.

  27. Horne AM, Mihov B, Reid IR. Bone loss after romosozumab/denosumab: Effects of bisphosphonates. Calcif Tissue Int 2018; 103(1): 55-61.

  28. Chapurlat R. Effects and management of denosumab discontinuation. Joint Bone Spine 2018; pii: S1297-319X(18)30001-0. Dostupné z DOI: <http://doi: 10.1016/j.jbspin.2017.12.013>.

Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology Osteology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#